| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Netgenics, Inc. |
| 1717 East Ninth Street, Suite 1600, Cleveland, OH 44114 * (216) 861-4007 |
| Business Description | The company is a leading provider of bioinformatics solutions. Our information technology solutions enable life science research companies to convert massive amounts of raw data into useful information that their scientists can use in the development of new drugs, gene therapies and agricultural products. |
|
Filing Information Not yet | ||||
| To Trade As | NTGC (NASNTL) | Industry | High-Tech (SIC 7371) | |
| Type of Stock Offered | Common Shares | Filing Date | 3/13/00 | |
| Domestic Shares Filed | 5,500,000 | Filing Range | $11.00 - $13.00 | |
| Foreign Shares Filed | 0 | Offering Amount | $66,000,000 | |
| Company Shares | 5,500,000 | Est. Expenses | - - | |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 23,485,387 | |
| Employees | 91 | |||
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | |||
| Revenues | - | 0.000 | 0.057 | 0.405 | 1.764 | - | - |
| Income from Oper. | - | -0.738 | -4.352 | -10.119 | -11.422 | - | - |
| Net Income | - | -0.730 | -4.233 | -9.635 | -11.265 | - | - |
| E.P.S | - | -0.500 | -1.470 | -3.330 | -3.820 | - | - |
| Revenue Growth (%) | - | - | 610.53 | 335.556 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.09 | - | - | ||||
| Cash Flow - Inv. | -0.79 | - | - | ||||
| Cash Flow - Fin. | 4.03 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 7.03 | Current Assets | 4.49 | Current Ratio | 0.90 |
| Total Liab. | 32.78 | Current Liab. | 5.02 | Debt Ratio | 466.09% |
| Total Equity | -25.75 | Working Cap. | -0.52 | Debt to Equity Ratio | - |
| Cash | 2.57 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Jones, Day, Reavis & Pogue |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Registrar/Transfer Agent | National City Bank |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| International Biotechnology Trust, plc | 7.70 | |
| College Retirement Equities Fund | 7.70 | |
| Venrock Associates II, L.P. and affiliates | 6.70 | |
| Edgewater Private Equity Fund II, L.P. | 6.60 | |
| Oxford Bioscience Partners II, L.P. and affiliates | 6.10 | |
| Affiliates of KECALP Inc., an affiliate of Merrill Lynch & Co. | 6.00 | |
| Incyte Pharmaceuticals, Inc. | 5.80 | |
| Affiliates of Orbimed Advisors, L.L.C. | 5.60 | |
| Lombard Odier & Cie | 5.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||